lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
| Property | Value | Notes |
|---|---|---|
| 储存温度 | 2 至 8 摄氏度 | 固体粉末，避光密封 |
| 外观 | 白色至类白色冻干粉 | 溶解后为澄清至微乳光 |
| 溶解性 | 易溶于水性缓冲液 | 避免剧烈振荡 |
| 常规纯度方法 | 反相高效液相色谱 | 紫外或质谱检测 |
| 定量方法 | 液相色谱串联质谱 | 配合固相萃取前处理 |
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
== Contraindications == The varicella vaccine is not recommended for seriously ill people, pregnant women, people who have tuberculosis, people who have experienced a serious allergic reaction to the varicella vaccine in the past, people who are allergic to gelatin, people allergic to neomycin, people receiving high doses of steroids, people receiving treatment for cancer with x-rays or chemotherapy, as well as people who have received blood products or transfusions during the past five months. Additionally, the varicella vaccine is not recommended for people who are taking salicylates (e.g. aspirin). After receiving the varicella vaccine, the use of salicylates should be avoided for at least six weeks. The varicella vaccine is also not recommended for individuals who have received a live vaccine in the last four weeks, because live vaccines that are administered too soon within one another may not be as effective. It may be usable in people with HIV infections who have a good blood count and are receiving appropriate treatment. Specific antiviral medication, such as acyclovir, famciclovir, or valacyclovir, are not recommended 24 hours before and 14 days after vaccination.
α-Methylphenylalanine (α-MePhe or AMPA) is an artificial amino acid and a phenethylamine and amphetamine derivative. It is the α-methylated analogue of phenylalanine, the precursor of the catecholamine neurotransmitters, and the amino acid analogue of amphetamine (α-methylphenethylamine), a psychostimulant and monoamine releasing agent. α-MePhe is a tyrosine hydroxylase inhibitor, thereby preventing the transformation of tyrosine into L-DOPA, and results in depletion of the catecholamine neurotransmitters. It is also an inhibitor of phenylalanine hydroxylase, and in conjunction with phenylalanine administration, induces hyperphenylalaninemia analogous to that in phenylketonuria in animals. The drug is known to produce metaraminol (3,β-dihydroxyamphetamine), a catecholamine releasing agent, as an active metabolite in animals, and this metabolite contributes to its effects. α-MePhe is a substrate of the L-type amino acid transporter 1 (LAT1), which transports it across the blood–brain barrier into the central nervous system.
where α is selectivity factor, N is the number of theoretical plates kA and kB are the retention factors of the two analytes. Retention factors are proportional to distribution coefficients. In practice substances with a selectivity factor very close to 1 can be separated. This is particularly true in gas-liquid chromatography where column lengths up to 60 m are possible, providing a very large number of theoretical plates. In ion-exchange chromatography the selectivity coefficient is defined in a slightly different way
The Quechua people (, US also ; Spanish: [ˈketʃwa] ) , Quichua people or Kichwa people are indigenous peoples of South America who speak the Quechuan languages, which originated among the Indigenous people of Peru. Although most Quechua speakers are native to Peru, there are some significant populations in Ecuador, Bolivia, Chile, Colombia, and Argentina.
Sources: en.wikipedia.org
In 2020, world production of soybeans was over 353 million tonnes, led by Brazil and the United States combined with 66% of the total (table). Production has dramatically increased across the globe since the 1960s, but particularly in South America after a cultivar that grew well in low latitudes was developed in the 1980s. The rapid growth of the industry has been primarily fueled by large increases in worldwide demand for meat products, particularly in developing countries like China, which alone accounts for more than 60% of imports. Soy is a staple crop; global soy production accounts for four times more legume production than all other legumes combined.
The clitoris and the labia minora are both the most erogenous areas of the vulva. The labia majora are also somewhat erogenous. Local stimulation can involve the clitoris, vagina and other perineal regions. The clitoris (especially the glans) is the human female's most sensitive erogenous zone and generally the primary anatomical source of human female sexual pleasure. Sexual stimulation of the clitoris (by a number of means) can result in widespread sexual arousal and, if maintained, can result in orgasm. Stimulation to vulvar orgasm is optimally achieved by a massaging sensation, such as oral sex (cunnilingus), fingering, and tribadism (two women rubbing vulvas together). Sexual arousal results in a number of physical changes in the vulva. During arousal, the Bartholin's glands produce more vaginal lubrication. Vulval tissue is highly vascularised; arterioles dilate in response to sexual arousal and the smaller veins will compress after arousal, so that the clitoris and labia minora increase in size. Increased vasocongestion in the vagina causes it to swell, decreasing the size of the vaginal opening by about 30%. Clitoral erection takes place, which retracts the clitoral hood, causing the glans to appear. The labia majora have swollen from blood flow, and slightly separated, revealing a thick and engorged labia minora. The labia minora sometimes change considerably in color, going from pink to red in lighter skinned women who have not borne a child, or red to dark red in those who have.
== Diseases of other endocrine glands (249–259) == Note: for 249–259, the following fifth digit can be added: (250.x0) Diabetes mellitus type 2 (250.x1) Diabetes mellitus type 1 (250.x2) Diabetes mellitus type 2, uncontrolled (250.x3) Diabetes mellitus type 1, uncontrolled 249 Secondary diabetes mellitus 249.0 Secondary diabetes mellitus without mention of complication 249.1 Secondary diabetes mellitus with ketoacidosis 249.2 Secondary diabetes mellitus with hyperosmolarity 249.3 Secondary diabetes mellitus with other coma 249.4 Secondary diabetes mellitus with renal manifestations 249.5 Secondary diabetes mellitus with ophthalmic manifestations 249.6 Secondary diabetes mellitus with neurological manifestations 249.7 Secondary diabetes mellitus with peripheral circulatory disorders 249.8 Secondary diabetes mellitus with other specified manifestations 249.9 Secondary diabetes mellitus with unspecified complications 250 Diabetes mellitus 250.0 Diabetes mellitus without mention of complication 250.1 Diabetes with ketoacidosis 250.2 Diabetes with hyperosmolarity 250.3 Diabetes with other coma 250.4 Diabetes with renal manifestations 250.5 Diabetes with ophthalmic manifestations 250.6 Diabetes with neurological manifestations 250.7 Diabetes with peripheral circulatory disorders 250.8 Diabetes with other specified manifestations 250.9 Diabetes with unspecified complication 251 Other disorders of pancreatic internal secretion 251.2 Hypoglycemia, nondiabetic, unspec. 252 Disorders of parathyroid gland 252.0 Hyperparathyroidism, unspec.
In the 16th century, European slave traders had begun to bring enslaved Africans to the Americas. Spain was the only European power that did not establish factories in Africa to purchase slaves; the Spanish Empire instead relied on the asiento system, awarding merchants from other European nations the license to trade enslaved peoples to their overseas territories. This system brought Africans to Colombia, although many spoke out against the institution. The indigenous peoples could not be enslaved because they were legally subjects of the Spanish Crown. To protect the indigenous peoples, several forms of land ownership and regulation were established by the Spanish colonial authorities: resguardos, encomiendas and haciendas. However, secret anti-Spanish discontentment was already brewing for Colombians since Spain prohibited direct trade between the Viceroyalty of Peru, which included Colombia, and the Viceroyalty of New Spain, which included the Philippines, the source of Asian products like silk and porcelain which was in demand in the Americas. Illegal trade between Peruvians, Filipinos, and Mexicans continued in secret, as smuggled Asian goods ended up in Córdoba, Colombia, the distribution center for illegal Asian imports, due to the collusion between these peoples against the authorities in Spain. They settled and traded with each other while disobeying the forced Spanish monopoly.
== Career and research == In 1984, Drucker began his research career at Massachusetts General Hospital and Harvard Medical School, studying molecular endocrinology in the lab of Professor Joel Habener with the support from a Medical Research Council of Canada Centennial Fellowship. Drucker’s independent discoveries in Boston included the demonstration that proglucagon could be cleaved into multiple glucagon-like peptides, including several distinct isoforms of GLP-1. He then discovered that the truncated form of GLP-1(7-37) directly stimulated cyclic AMP formation, insulin secretion, and insulin gene expression; notably, it did so only when glucose levels were elevated.
Sources: en.wikipedia.org
建议在低温、避光、干燥环境中密封保存，常见条件为 2 至 8 摄氏度，长期存放可置于更低温度。应避免反复冻融，并尽量减少容器开启次数。
溶解后的稳定时间通常短于固体形态，受浓度、缓冲液和容器材质影响。冷藏条件下一般只能维持较短时间，具体期限应通过实际稳定性实验确认。
反相高效液相色谱用于纯度与含量测定，液相色谱串联质谱用于生物基质中的定量，体积排阻色谱用于检测聚集体。多种方法结合才能较完整地表征样品。
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.